ABIGAIL CRUMMITT: Open Payments
NPI 1275916512 · WHEELING, WV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,344 in 110 payments from 14 companies in 2025. Trend: 2023 $1,300 · 2024 $1,728 · 2025 $2,344
Food & beverage: $2,344
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 20 | $496 |
| Novartis Pharmaceuticals Corporation | 22 | $416 |
| GlaxoSmithKline, LLC. | 17 | $294 |
| GENZYME CORPORATION | 11 | $261 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $215 |
| Amgen Inc. | 8 | $181 |
| Genentech USA, Inc. | 5 | $119 |
| ARS Pharmaceuticals Operations, Inc. | 6 | $107 |
| CSL Behring | 3 | $77 |
| PFIZER INC. | 4 | $66 |
Products named: DUPIXENT, XOLAIR, NUCALA, FASENRA, TEZSPIRE, AIRSUPRA, HYQVIA, Rhapsido.
Industry payments across WV — which companies pay providers there.
